Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Liposomes are made of cholesterol and natural non-toxic phospholipids, and lipid nanoparticles are nanoparticles composed of lipids. Both are advanced drug delivery systems designed to protect loaded drug molecules from external degradation, and their similarity to biomembranes allows them to evade attacks from the body's immune system, providing the ability to deliver drug molecules to cells or Opportunities in subcellular compartments.

Market Overview:

The latest research study on the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market finds that the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market reached a value of USD 7382.11 million in 2022. It’s expected that the market will achieve USD 10696.83 million by 2028, exhibiting a CAGR of 6.38% during the forecast period.

The field of an application continues to expand

Lipid nanoparticles (LNPs) have attracted considerable attention in the pharmaceutical industry as promising carriers of various therapeutic drugs. Especially at present, LNPs are the key components of mRNA vaccines, an important weapon against the COVID-19-19 epidemic, and play an important role in effectively protecting mRNA and transporting it to cells. Liposomes, the earliest LNPs, can transport hydrophobic or hydrophilic molecules, including small molecules, proteins, and nucleic acids. It is a widely used nanocarrier platform. In fact, liposome is also the first type of nano drug delivery platform that has been successfully transformed from concept to clinical application. Several liposome pharmaceutical preparations have been approved for marketing and successfully applied in medical practice. A new generation of LNPs, including solid lipid nanoparticles, nanostructured lipid carriers, and cationic lipid-nucleic acid complexes, exhibits more complex internal structures and better physical stability. LNPs can control the target location and timing of drug delivery in vivo and can provide therapeutic options for a variety of diseases. The application fields of liposome and lipid nanoparticle drug delivery systems continue to expand, driving the overall growth of market demand.

Region Overview:

In 2022, the share of the Liposomal and Lipid Nanoparticle Drug Delivery Systems market in United States stood at 36.14%.

Company Overview:

Pfizer is a leading research-based biopharmaceutical company. Dedicated to the discovery, development, manufacture and marketing of prescription medicines for humans and animals. Headquartered in New York City.

Segmentation Overview:

By type, Lipid Nanoparticle Drugs segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Retail Pharmacy segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market covered in Chapter 3:

Pacira
Ipsen
Leadiant Biosciences
TTY Biopharma
Teva
Gilead Sciences
Fudan-Zhangjiang
BMS
CSPC
Johnson and Johnson
Luye Pharma Group
Kinyond
Alnylam
Sun Pharmaceutical
Acrotech Biopharma (Spectrum)

In Chapter 4 and Chapter 14.2, on the basis of types, the Liposomal and Lipid Nanoparticle Drug Delivery Systems market from 2018 to 2029 is primarily split into:

Liposomes Drugs
Lipid Nanoparticle Drugs

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Liposomal and Lipid Nanoparticle Drug Delivery Systems market from 2018 to 2029 covers:

Hospital
Retail Pharmacy
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)